Dxplora diagnostics development and manufacturing coordination

LDT PCR Workflows: Laboratory Responsibilities vs. Supplier Responsibilities

A clear division of responsibilities between a CLIA laboratory and a PCR reagent development or manufacturing supplier.

LDT PCR Workflows: Laboratory Responsibilities vs. Supplier Responsibilities

Key takeaways

  • The laboratory owns intended use, performance specifications, validation, implementation, and patient-result reporting.
  • A supplier can develop or configure reagents, produce evaluation material, document lots, and support manufacturing continuity.
  • A certificate, specification, or supplier release test does not replace laboratory evaluation.
  • A written responsibility matrix prevents assumptions at the boundary between reagent supply and laboratory practice.

In an LDT PCR workflow, the laboratory and reagent supplier contribute different forms of control. The supplier can create and document a defined material. The laboratory decides how that material is used in its test, establishes performance specifications, evaluates the complete workflow, and remains responsible for quality and reporting within its regulatory and accreditation context.

What the laboratory owns

The laboratory defines intended use, specimen type, patient population, methodology, performance specifications, acceptance criteria, study design, quality-control procedures, personnel competency, implementation, ongoing monitoring, and result reporting. These decisions cannot be transferred to a reagent supplier through a purchase order.

What a development or manufacturing supplier owns

Within the contracted scope, the supplier controls formulation or configuration work, raw-material specifications, manufacturing instructions, lot identification, in-process controls, release checks, packaging, storage instructions, and agreed change communication. The supplier should state what was tested and avoid implying conclusions beyond that scope.

What Dxplora coordinates

Dxplora can coordinate technical scoping, partner selection, baseline review, assay or format development, evaluation and pilot quantities, packaging considerations, documentation expectations, and repeat-supply planning. Dxplora is not the testing laboratory and does not report patient results.

Where misunderstandings occur

Common boundary problems include treating supplier QC as laboratory validation, assuming a custom reagent is cleared or approved because it was manufactured under a quality system, changing an oligonucleotide or master mix without assessing workflow impact, and failing to define who investigates a lot-to-lot difference.

Create a responsibility matrix

For each deliverable, name the owner, input, output, review step, acceptance decision, record location, and change process. The matrix should cover sequences, chemistry, controls, evaluation material, laboratory studies, specifications, release information, shipping, storage, complaints, and future changes.

Keep claims proportional to evidence

Supplier documentation can accurately describe the material and work performed. Laboratory evidence supports conclusions about the laboratory's complete test workflow. Marketing and technical language should preserve that distinction and avoid implying clinical status that has not been established.

Frequently asked questions

Can a reagent supplier establish an LDT's performance specifications for the laboratory?

The supplier may provide technical information, but the laboratory defines and establishes performance specifications for its test and setting.

Does a certificate of analysis replace laboratory evaluation?

No. It reports tests performed on the supplied material and does not establish performance of the laboratory's complete workflow.

Can Dxplora run the laboratory's validation process?

Dxplora's current role is development and manufacturing coordination. The laboratory owns its study design, validation, implementation, and patient-result reporting.

Primary references